241 related articles for article (PubMed ID: 28182990)
1. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
2. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
[TBL] [Abstract][Full Text] [Related]
3. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
4. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
[TBL] [Abstract][Full Text] [Related]
7. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
8. Urea-containing peptide boronic acids as potent proteasome inhibitors.
Han LQ; Yuan X; Wu XY; Li RD; Xu B; Cheng Q; Liu ZM; Zhou TY; An HY; Wang X; Cheng TM; Ge ZM; Cui JR; Li RT
Eur J Med Chem; 2017 Jan; 125():925-939. PubMed ID: 27769033
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
11. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
13. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors.
Uysal S; Soyer Z; Saylam M; Tarikogullari AH; Yilmaz S; Kirmizibayrak PB
Eur J Med Chem; 2021 Jan; 209():112890. PubMed ID: 33039723
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.
Han L; Wen Y; Li R; Xu B; Ge Z; Wang X; Cheng T; Cui J; Li R
Bioorg Med Chem; 2017 Aug; 25(15):4031-4044. PubMed ID: 28634039
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors.
Xu K; Xiao Z; Tang YB; Huang L; Chen CH; Ohkoshi E; Lee KH
Bioorg Med Chem Lett; 2012 Apr; 22(8):2772-4. PubMed ID: 22437113
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]